Age at start of vaccine course

MenACWY vaccine brand

Dose requirements for people with a specified medical condition associated with increased risk of meningococcal disease

6 weeks to 5 months

Menveo

Nimenrix

4 doses (8 weeks between doses; 4th dose at 12 months of age or 8 weeks after 3rd dose, whichever is later)

6–8 months

Menveo

Nimenrix

3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later)

9–11 months

Menveo

Nimenrix

Menactra

3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later)

≥12 months

Menveo

Nimenrix

Menactra

2 doses (8 weeks between doses)

Booster doses for all ages

Menveo

Nimenrix

Menactra

For people with ongoing increased risk of invasive meningococcal disease who completed the primary series at:

  • ≤6 years of age — 3 years after completing the primary schedule, then every 5 years after that
  • ≥7 years of age — every 5 years after completing the primary schedule
Previous

Table. Recommendations for immunisation of infants and children aged

Next

Table. Recommendations for MenB vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease

Last updated: 
5 June 2018
Last reviewed: 
5 June 2018